Search Results for "Ranbaxy Launches Atorvastatin In Us"

17:37 EDT 21st October 2014 | BioPortfolio

Matching Channels

Lipitor

Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is pres...

Matching News

U.S. Pay-To-Delay Suit Against Ranbaxy, Pfizer Rejected

A U.S. judge threw out a suit filed against Ranbaxy Laboratories and Pfizer alleging they colluded to delay the market introduction of a generic of the top-selling Lipitor (atorvastatin) for high chol...

Sun Pharma Set For Bumpy Drive To Reach Ranbaxy

Analysts are growing cautious on the mega Sun-Ranbaxy deal, raising doubts on the timelines for regulatory approvals and the fallout of court proceedings. Some have questioned if an open bidding proce...

Cipher Pharmaceuticals signs distribution agreement with Ranbaxy

MISSISSAUGA, ON- Cipher Pharmaceuticals Inc. announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Ltd., granting Ranbaxy exclusive rights to market, sell and dis...

Ranbaxy’s Valsartan ANDA Wins FDA Approval After Lengthy Delay

Regulatory nod gives Ranbaxy green light to launch its generic version of Novartis’ Diovan with 180-day exclusivity; other ANDA holders may continue to challenge Ranbaxy’s hold on the market.

Sun Pharma denies unit's role in Ranbaxy share run-up before deal

MUMBAI, May 5 (Reuters) - India's Sun Pharmaceutical Industries Ltd, which is to buy rival drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, said its unit Silverstreet Developers LLP had no role to...

Ranbaxy’s manufacturing woes benefit big pharma

Import bans by the US Food and Drug Administration (FDA) on generics from four of Ranbaxy Laboratories’ (Ranbaxy) manufacturing sites have prevented the company from launching new generics, allowing...

Court stops Ranbaxy takeover

An Indian court has stopped the sale of Ranbaxy Laboratories to Sun Pharmaceutical Industries after concerns were raised over insider dealing, according to media reports. Sun agreed to buy struggling ...

Sunshine finally: Ranbaxy gets FDA ok for Diovan generic

Finally, the sun seems to be shining on Ranbaxy. Ending prolonged speculation on the fate of its generic version of Novartis's blockbuster blood pressure treatment Diovan (valsartan) amid mounting pre...

Matching PubMed Articles

Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

Now that generic atorvastatin has become available, a process of switching from rosuvastatin to atorvastatin may occur and could persist until the patent on branded rosuvastatin expires. It is importa...

Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.

The objective of the present study was to develop bilayer tablets of atorvastatin and atenolol that are characterized by initial fast-release of atorvastatin in the stomach and comply with the release...

Efficacy and Safety of Alternate Day Therapy With Atorvastatin and Fenofibrate Combination in Mixed Dyslipidemia: A Randomized Controlled Trial.

Introduction:The long half-life of atorvastatin and fenofibrate makes them suitable for alternate day therapy. Hence, we aimed to study the efficacy, safety, and cost-effectiveness of alternate day th...

Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial.

Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvasta...

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement